James T.
Healthcare
James Talbot, MSc, is a medical author specializing in evidence-based healthcare content. He holds a Master's degree in Biomedical Sciences from the University of Leeds and has over eight years of experience researching and writing medical articles for patient and professional audiences.
Before becoming an independent medical author, James worked as a medical writer and content specialist for Elsevier and later IQVIA, where he contributed to clinical education materials, literature reviews, and healthcare publications. His work focuses on translating peer-reviewed research and clinical guidelines into clear, accurate, and accessible content covering topics such as cardiovascular health, infectious diseases, and preventive medicine.
Email: james.t@mavengity.com
Top 6 articles by James T.
A Diabetes Group Fought for Editorial Independence in 2015. Now It's Suppressing Its Own. The Difference Is Who It Costs.
Defending a principle when it costs nothing reveals little. The ADA's reversal from defender to suppressor of editorial independence shows what happens when upholding it would cost something real.
The FDA Halted Every Trial Using One Vector and Restored Only One. The Inconsistency Is More Defensible Than It Looks.
Safety risk from a shared vector genuinely aggregates across programs while disease-specific benefit does not. The real grievance isn't the inconsistency, it's a process that counts the harm of acting and ignores the harm of waiting.
Novo Nordisk's Drug Lowered Inflammation Perfectly. It Prevented Zero Heart Attacks. That Gap Is Why Outcomes Trials Exist.
A hazard ratio of 0.99 sitting under a perfect-looking set of inflammation numbers is the cleanest possible demonstration that moving a biomarker and helping a patient are not the same thing.
Syphilis Is Curable With a Cheap, 80-Year-Old Shot. Every Reason It's Spreading Is a System Failure.
Nothing about syphilis got harder to treat. What decayed is everything around the cure: manufacturing resilience, the one drug pregnant patients have no substitute for, and the surveillance that finds hidden cases.
The FDA's Advisers Backed a Drug They Couldn't Fully Interpret and Rejected One They Called a "Mirage." The Difference Is Trust.
An honest design limitation is forgivable. A benefit that appears only after the analysis plan changed after the fact is not. That distinction, not data quality alone, explains why one panel voted 10-3 to endorse and the other 3-9 to reject.
Cassidy Traded His Vote for Assurances Once Before. Those Reportedly Broke. He Just Did It Again.
A confirmation vote is a one-time, irreversible payment. A private promise is a revocable one. Cassidy has now made that exact trade twice with the same department, and the first round reportedly did not hold.